Engraftment after myeloablative doses of 131I- Metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma

Medical and Pediatric Oncology

Volumn 30, Issue 6, 1998, Pages 339-346

  Goldberg, S S ^a   Desantes, K ^a   Huberty, J P ^a   Price, D ^a   Hasegawa, B H ^a   Reynolds, C P ^a   Seeger, R C ^a   Hattner, R ^a   Matthay, K K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone marrow; Engraftment; Metaiodobenzylguanidine; Myeloablative treatment; Neuroblastoma; Transplantation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; HYPOTHYROIDISM; MALE; NAUSEA; NEUROBLASTOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING; WHOLE BODY RADIATION;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0031960991     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199806)30:6<339::AID-MPO7>3.0.CO;2-F     Document Type: Article

References (24)